Release of the top 25 pharmaceutical companies with the highest market value in the world

Source: global data, a global well-known pharmaceutical industry research institution of sina pharmaceutical 2018-04-08, recently released the top 25 pharmaceutical company with the highest market value in the world The statistics of this report are as of the end of 2017 In the report, GlobalData analyzed the business performance of major pharmaceutical companies in 2017 based on a number of key indicators to assess their health, including: market value (M Cap), P / E, EPS, EV / EBITDA, roce, ROA, R & D expenses as a percentage of sales revenue, operating gross profit, etc The report reveals many interesting insights Compared with 2016, the performance of major pharmaceutical companies in 2017 is mixed: only half of the top 25 pharmaceutical companies achieved double-digit growth in market value, and another five companies saw market value decline, including MSD, Xinji, GSK, Erjian and shire The three giants, Johnson & Johnson, Roche and Pfizer, have a solid industrial position and continue to maintain the top three Other highlights in the top 25 list include: vertex's performance is far better than that of most companies Thanks to the excellent performance of a breakthrough cystic fibrosis drug in multiple clinical studies, the company's market value doubled in 2017, reaching US $40 billion; Abbott and Aberdeen have benefited from the potential late stage clinical pipeline assets, and their market value has increased by more than 50% in 2017; Novo Nordisk and Bayer have successfully ranked in the top 10 in 2017, while both of them are outside the top 10 in 2016 In 2017, the market value of these two companies has increased by more than $1 billion, which is mainly due to the strong growth of sales Global data chief analyst Amal George commented that Novo Nordisk's sales growth mainly came from diabetes and obesity care products, such as tresiba, Victoza and saxenda brands, while Bayer benefited from the division of its materials technology company covestro and sales growth from the core pharmaceutical brands xarlto, eyla, Mirena and xofigo It is worth noting that Pfizer and Roche have expanded their cancer pipeline assets with us $14 billion for medivation and US $1.7 billion for ignyta, respectively, while Johnson & Johnson has performed strongly in the pharmaceutical industry through a series of acquisition transactions, including US $30 billion for actelion Overall, top 25 pharmaceutical companies reported a robust average operating margin of 22%, while top 10 pharmaceutical companies reported 25% According to the report, the average market value of top 25 pharmaceutical companies reached US $24.9 billion, with an average p / E of 34.7% (except fortay pharmaceutical and Elgin), and an average EPS of US $4.5 (both of which are negative), including Pfizer's EPS of US $1.2 Top 25 pharmaceutical companies have an average ROA of 9% and roce of 16.2% 14 companies have reached the double-digit roce, among which Novo Nordisk has reached 96.7% According to the report, top 25 pharmaceutical companies continued to invest heavily in R & D in 2017, with an average R & D / sales ratio of 18.2% (fotna 96.5%) In addition, these pharmaceutical giants are also very active in the acquisition and development of partnerships, such as Johnson & Johnson and Schering plough, Mitsubishi Tianbian pharmaceutical, GlaxoSmithKline, Alkermes, Futai pharmaceutical, Bayer, Pfizer and celltrion, MSD and Astaire Here is a detailed list of the top 25 pharmaceutical companies with the highest market value in the world (compiled by Sina pharmaceutical / newborn)